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Objectives: Patients, physicians, and other decision-makers make implicit trade-
offs among benefits and risks of different treatments. Many methods have been 
proposed to conduct quantitative benefit-risk analysis (BRA). We propose a frame-
work for classifying BRA methods based on factors that matter most to patients. 
Using common mathematical notation, we compare the methods using a hypo-
thetical example. MethOds: We classified available BRA methods into three cat-
egories: (1) un-weighted metrics, that use only probabilities of benefits and risks 
(e.g., number needed to treat and number needed to harm [NNT|NNH]); (2) metrics 
that incorporate preference weights to account for the impact and duration of out-
comes (e.g., Maximum Acceptable Risk [MAR], relative value-adjusted life-years 
[RVALYs], quality-adjusted life-years [QALYs]); and (3) metrics that incorporate 
ad hocweights based on decision makers’ opinions (e.g., Multi-criteria Decision 
Analysis, Benefit-Less-Risk Analysis). We used two hypothetical antiplatelet drugs 
(A and B), probabilities of benefits (reduction in myocardial infarction and stroke) 
and harms (increases in major and minor bleeding) based on randomized trial data, 
and preference weights from the literature to compare the BRA methods within 
the proposed framework. Results: Use of the framework and notation revealed 
BRA methods share substantial commonality. In the example, BRA using NNT|NNH 
indicated that -1.3% of patients would experience net benefit with drug A versus 
B, (an unfavorable benefit-risk balance for A). In contrast, 4.6% of patients would 
experience a net benefit with drug A if weighted using MAR. BRA using RVALYs and 
QALYs suggested gains of 3.8 RVALYs and 5.4 QALYs per 100 patient-years, respec-
tively, with drug A versus B. cOnclusiOns: The proposed framework provides 
a unified, patient-centered approach to BRA methods classification. All methods 
impose trade-offs between probabilities of benefits and risks. The weights used 
in the metrics is a key differentiating feature and can lead to quantitatively and 
qualitatively different results.
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Objectives: Network meta-analysis (NMA) is being increasingly used in the eco-
nomic evaluation of medical interventions. One potential advantage of NMA is that 
through stratified analysis it can allow comparison of treatments even when trial 
populations are not homogenous. Such analyses can then facilitate stratified cost 
effectiveness analysis (CEA). This is illustrated through the example of antithrom-
botic treatments for atrial fibrillation (AF) with stratification based on a clinical 
prediction rule (CHADS2). MethOds: Clinical trials in patients with non-valvular 
AF requiring anticoagulation were identified. A Bayesian mixed treatment compari-
son NMA was conducted for stroke, mortality, major bleeding, intracranial hemor-
rhage and myocardial infarction. Where available clinical trial data was obtained 
by CHADS2 score and analysis conducted within three sub groups (CHADS2 score 
< 2, = 2, > 2). Data for warfarin, apixaban, dabigatran 110mg and 150mg (twice daily), 
rivaroxaban, low and medium dose ASA, and clopidogrel plus ASA were available. 
A CEA stratified by CHADS2 score was conducted using a previously published eco-
nomic model. Results: For patients with a CHADS2 score < 2 and = 2, the incre-
mental cost utility ratio, ICUR for dabigatran 150mg versus warfarin was $20,845 
and $23,688 respectively: in both scenarios dabigatran 150mg dominated all other 
alternatives. For patients with a CHADS2 score > 2, the ICUR for apixaban versus 
warfarin was $2,402: apixaban dominated all other alternatives. cOnclusiOns: 
Based on current Canadian thresholds for cost effectiveness, dabigatran 150 mg 
bid was optimal for patients with a CHADS2 score < 2 and = 2, whilst apixaban was 
optimal for patients with a CHADS2 score > 2. This study highlights how NMA can 
be combined with stratified CEA to facilitate meaningful policy recommendations.
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Objectives: Recent legislation in Massachusetts promotes population health 
improvement while creating incentives to control health care costs. This research 
creates a tool that projects population health in order to predict health care use and 
spending, and to help policy makers make decisions about the allocation of health 
care resources. MethOds:  The Population Health Model is a micro-simulation that 
projects the health status and health care costs for Massachusetts residents over 
50. Drawing from the 1992-2010 Health and Retirement Study, we created modules 
for cancer, heart disease, COPD, diabetes, hypertension, stroke, and mortality risk 
using non-parametric survival analysis which adjusted for demographics, insurance 
status, smoking history, weight, and concurrent diseases. The model simulated indi-
vidual health trajectories over 5 years based on the 2011 state subset of Behavioral 
Risk Factor Surveillance System data. Results:  The model projected that for the 
Massachusetts 2011 cohort, starting disease prevalence rates were 13.5% for diabe-
tes, 42.9% for hypertension, 9.3% for heart disease, 10.6% for cancer, 8.2% for COPD, 
and 3.6% for stroke. Over 5 years, projected incidence rates for this population were 
Medtronic Corevalve (MC)) versus conventional surgery using data from “real-life” 
patients. MethOds: Prospective recruitment in 7 Spanish hospitals, with follow-
up at one, three and six months after intervention. We measured utility with EQ5D. 
We estimated crude and adjusted differences in costs and QALYs using regression 
analyses with bootstrap estimation of variance. We calculated incremental cost-
utility ratios (ICER) comparing ES and MC to AVR and derived cost-effectiveness 
acceptability curves. Subgroup and sensitivity analyses were performed. Results: 
Data from 48 ES-TAVI, 86 MC-TAVI and 52 AVR patients were analyzed; 4 were lost 
to follow up. Mean STS risk score was: ES: 4.9 (3), MC: 5.1 (3), AVR: 5.1 (2). Overall 
cost of ES-TAVI was 7,202 € higher than AVR (adjusted difference: 5,474; 95%CI: 926-
11,875) and the difference in QALYs was 0.045 (adjusted difference: 0.041; 95%CI: 
-0.015 – 0.96), resulting in an ICER of 161,086 € /QALY. The cost of MC-TAVI was 7,476 
€ higher than AVR (adjusted difference: 8,738; 95%CI: 4,480 – 12,997) and the differ-
ence in QALYs was 0.003 (adjusted difference: 0.025; 95%CI: -0.027 – 0.77), resulting 
in an ICER of 2,451,568 € /QALY. The results were mainly driven by the high cost of 
the TAVI device and did not substantially change in the sensitivity analysis and 
subgroups. cOnclusiOns: In the Spanish setting, the use of transfemoral TAVI 
when surgery is feasible is not likely to be cost-effective at a willingness-to-pay 
threshold of 30,000 € /QALY.
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Objectives: Big data has the potential to provide tremendous value to health care 
manufacturers, improving their understanding of unmet clinical need and inform-
ing product development. The objective of this study was to analyze leading payer 
claims databases and EMR systems for diagnostic specific information and costs 
and to determine where unmet needs and opportunities for future data optimiza-
tion exist. MethOds: Five companies who sell large claims and EMR data sets were 
interviewed to understand costs and data granularity. Additionally, interviews were 
conducted with three diagnostic companies that recently purchased big data sets to 
better understand the opportunities and limitations of the data purchased related to 
diagnostic decision-making and research. Results: Datasets reviewed contained 
little granularity related to diagnostic tests. Specifically, because individual tests 
cannot be determined by CPT code, there was no way to determine the brand of 
test used or whether tests were FDA-approved or laboratory developed. Additionally, 
neither claims databases nor EMR systems capture the diagnostic platform used 
for laboratory analysis. There was variation in the detail contained in the databases 
related to lab results. EMR systems seemed to contain greater detail than claims 
system, but lack standards, making it hard to combine data sets. Diagnostic com-
panies are more likely than other health care manufacturers to be small compa-
nies with limited budgets. The current cost of purchasing data, excluding analysis, 
is estimated to be between $25,000 and $200,000. cOnclusiOns: Despite their 
potential, claims and EMR data sources have significant limitations in the detail 
they can provide related to diagnostic and lab services. Additionally, big data is not 
affordabile for many diagnostic companies. As a result, diagnostic companies face 
challenges in demonstrating both shortcomings of existing approaches and the 
clinical and cost utility of novel tests. As diagnostics become more central to health 
decision-making and personalized medicine, data sources need to address existing 
limitations to better demonstrate their clinical and economic impact.
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Objectives: Mitral regurgitation (MR), a cardiac disease resulting in volume 
overload, is associated with an increased risk of heart failure and mortal-
ity. Standard care for MR is surgical repair or replacement of the mitral valve. 
Patients at high risk for surgical intervention, such as those with functional MR, 
are often relegated to medical management alone. The MitraClip is a transcath-
eter device, which performs percutaneous edge-to-edge repair to treat MR. We, 
evaluated the real-world clinical and cost effectiveness of MitraClip in high-risk 
MR patients. MethOds: Data for patients receiving MitraClip were obtained 
from a prospective registry of high-risk MR patients treated at the Montreal Heart 
Institute (MHI) in Quebec from December 2010 to May 2013. These patients were 
propensity matched on baseline characteristics and medical therapy to medically 
treated MR patients followed at the MHI Heart Failure Clinic from 2008 to 2011. 
Cohorts were compared on clinical and economic outcomes, quality of life (QoL), 
complications/adverse events, emergency room (ER) visits, hospitalizations, 
surgical intervention, and clinic visits. Based on data from this matched com-
parison, we then developed a decision analytic model to assess the incremental 
cost-effectiveness of MitraClip vs. medical therapy in patients with high-risk 
MR. Survival for each group was extrapolated beyond follow-up to 10 years using 
Weibull regression. Unit costs were obtained from the MHI. Costs and benefits 
were discounted at 5% per annum. One-way and probabilistic sensitivity analyses 
were performed. Results: Compared with medical therapy, treatment with Mi-
traClip was associated with a gain of 1.34 quality-adjusted life years (QALYs) and 
an incremental cost of $48,970 (Canadian). The incremental cost-effectiveness 
ratio (ICER) was $36,543 per QALY gained. cOnclusiOns: Based on data from 
our matched, observational comparison, treatment with the MitraClip appears 
to be an economically attractive alternative to medical therapy for high-risk 
patients with MR.
